Research Topics
| Anne CorbettSummaryCountry: UK Publications
| Collaborators
|
Detail Information
Publications
Treatment of behavioral and psychological symptoms of Alzheimer's diseaseAnne Corbett
Alzheimer s Society UK, Devon House, London, UK
Curr Treat Options Neurol 14:113-25. 2012..Large, prospective, randomized placebo-controlled trials are needed to establish the role of these agents as clinical therapies for the treatment of BPSD...
Alzheimer's diseaseClive Ballard
Wolfson Centre for Age Related Diseases, King s College London, London, UK
Lancet 377:1019-31. 2011..In this Seminar, we provide an overview of recent evidence regarding the epidemiology, pathogenesis, diagnosis, and treatment of Alzheimer's disease, and discuss potential ways to reduce the risk of developing the disease...
Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trialMarisa Hanney
Wolfson Centre for Age Related Diseases, King s College London, London, UK
Lancet 379:528-36. 2012..Evidence to support treatment with Alzheimer's drugs is inadequate, although memantine is beneficial in transgenic mice. We aimed to assess safety and efficacy of memantine on cognition and function in individuals with Down's syndrome...
Management of neuropsychiatric symptoms in people with dementiaClive Ballard
Wolfson Centre for Age Related Diseases, King s College London, London, UK
CNS Drugs 24:729-39. 2010..Adequately powered randomized controlled trials for the treatment of clinically significant agitation are urgently needed to explore alternative pharmacological therapies...
Information provision services in dementia careAnne Corbett
Alzheimer s Society Research, London, UK
Int J Older People Nurs 6:217-26. 2011....
Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortalityClive Ballard
Wolfson Centre for Age Related Diseases, Wolfson Wing, King s College London, Guy s Campus, Hodgkin Building, London, UK
Expert Opin Drug Saf 10:35-43. 2011..The benefits are less clear-cut with longer term prescribing, but the mortality risk remains significantly elevated. Pharmacogenetics may provide an opportunity to more effectively focus prescribing in the future...
